

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

Mouse Anti-Human CD133/2 (293C3) Monoclonal Antibody, PE Conjugated Clone 293C3

RRID:AB_244346

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-090-853, RRID:AB_244346

Antibody Information

URL: http://antibodyregistry.org/AB_244346

Proper Citation: Miltenyi Biotec Cat# 130-090-853, RRID:AB_244346

Target Antigen: Mouse Human CD133/2 (293C3) PE Clone 293C3

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 4-2018; manufacturer recommendations: Mouse IgG2b Flow cytometry; Immunofluorescence
Detection of human stem and progenitor cells; Flow Cytometry; Immunofluorescence
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-186. (RRID:AB_2726012).

Antibody Name: Mouse Anti-Human CD133/2 (293C3) Monoclonal Antibody, PE Conjugated Clone 293C3

Description: This monoclonal targets Mouse Human CD133/2 (293C3) PE Clone 293C3

Target Organism: human

Antibody ID: AB_244346

Vendor: Miltenyi Biotec

Catalog Number: 130-090-853

Record Creation Time: 20250820T031301+0000

Record Last Update: 20250820T153934+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Human CD133/2 (293C3) Monoclonal Antibody, PE Conjugated Clone 293C3.

Warning: Discontinued: 2021

Discontinued: 4-2018; manufacturer recommendations: Mouse IgG2b Flow cytometry; Immunofluorescence

Detection of human stem and progenitor cells; Flow Cytometry; Immunofluorescence

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-186. (RRID:AB_2726012).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang L, et al. (2026) Predictive prioritization of enhancers associated with pancreatic disease risk. *Cell genomics*, 6(1), 101040.

Verhagen MP, et al. (2024) The SW480 cell line as a model of resident and migrating colon cancer stem cells. *iScience*, 27(9), 110658.

Sobrinho S, et al. (2023) Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy. *Cell reports. Medicine*, 4(2), 100919.

Tatar C, et al. (2023) Doxorubicin-induced senescence promotes resistance to cell death by modulating genes associated with apoptotic and necrotic pathways in prostate cancer DU145 CD133+/CD44+ cells. *Biochemical and biophysical research communications*, 680, 194.

Zhu P, et al. (2022) 5-hydroxytryptamine produced by enteric serotonergic neurons initiates colorectal cancer stem cell self-renewal and tumorigenesis. *Neuron*, 110(14), 2268.

Schiroli G, et al. (2019) Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response. *Cell stem cell*, 24(4), 551.

Petrillo C, et al. (2018) Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. *Cell stem cell*, 23(6), 820.

Zaikos TD, et al. (2018) Hematopoietic Stem and Progenitor Cells Are a Distinct HIV Reservoir that Contributes to Persistent Viremia in Suppressed Patients. *Cell reports*,

25(13), 3759.